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etter to the Editor – Brief Case Reports
he evolution  of  occult  Hepatitis  C Virus  after
mmunosuppression in  advanced  CKD  patients
volución  del  virus  de  la  hepatitis  C  oculto  tras  inmunosupresión  en
a
there was an immune response (Fig. 1). In March and April
2009, there was a transient mild increase in ALT, with a maxi-nfermedad  renal  crónica  avanzad
o the Editor,
epatitis C Virus (HCV) affects prognosis in patients with
dvanced chronic kidney disease (ACKD). A high prevalence of
lassic and occult HCV has been described in the haemodial-
sis population.1,2 Although we are in a new era of antiviral
reatment, there are no studies supporting the indication of
his therapy in patients with occult HCV infection yet. The
CKD population that is to receive future immunosuppres-
ion appears to be at risk for viral replication. Therefore,
t would bear considering pre-immunosuppression antiviral
reatment.3 There is just 1 published case on the subject,
lthough that patient did not have renal disease.4 This let-
er presents the clinical course of occult HCV in 2 patients
ith ACKD who  received immunosuppressive therapy. The
etermination of occult HCV was performed in la Fundación
ara el Estudio de las Hepatitis Virales (the Foundation for
he Study of Viral Hepatides), using ultracentrifugation of
erum5 and ultrasensitive PCR in the liver and in peripheral
lood mononuclear cells (PBMC).6 In recent years, the high-
ensitivity anti-HCV core antibody detection technique has
een added.7
ase  1
 40-year-old woman, smoker, with systemic lupus erythe-
atosus, antiphospholipid syndrome, hypertension, tertiary
yperparathyroidism, osteoporosis, hyperhomocysteinaemia,
DOI of original article:
ttp://dx.doi.org/10.1016/j.nefro.2015.06.005.
 Please cite this article as: Martín-Gómez MA, Castillo-Aguilar I, Barr
abello-Díaz M. Evolución del virus de la hepatitis C oculto tras inmun
015;35:511–513.and hyperuricaemia. She began haemodialysis in 1990
(renal transplant from 1991 to 1998). Regular medications
were cinacalcet, aluminium hydroxide, calcium acetate, rise-
dronate, folic acid, multivitamin B1/B6/B12, omeprazole,
allopurinol, carvedilol, hydroxychloroquine, acenocoumarol,
iron, and intradialytic darbopoetin.
From March 2008, serial “indeterminate” results were
ascertained (ELISA, RIMA) for HCV (positive only for the NS3
fraction). Several retests were carried out, and cross-reaction
testing was performed for underlying autoimmune disease.
Despite normal blood transaminase levels, the possibility was
raised of occult HCV. This was conﬁrmed in peripheral blood
mononuclear cells (PBMC, 1170 copies/g total RNA), and in
the liver. Further investigations were performed: transjugu-
lar liver biopsy, showing chronic hepatitis grade/stage 0/0;
FibroScan®, 6.3 KPa; APRI, 0.81; and Forns score, 7.59. Poten-
tial external contamination was tested for, but did not occur:
viral PCR and serology were performed on the other patients
in the unit and the healthcare staff. No new cases of clas-
sic HCV infection were detected. In February 2009, the patient
received intravenous immunoglobulin IVIG (2 g/kg) for pre-
transplant desensitisation (in the end, transplant was not
performed, for other reasons), and from June to November
2009 she received azathioprine (AZT 50 mg/day) and corti-
coid therapy (GC 5 mg/day) for lupus activity. There was no
observed increase in the intralymphocyte viral load, althoughil-Cuadrado G, Cabezas-Fernández T, Casado-Martín M,
osupresión en enfermedad renal crónica avanzada. Nefrologia.
mum level of 42 UI/L.
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Fig. 1 – Changes in conventional anti-HCV antibodies and occult HCV viral load. Laboratory threshold for positivity for
anti-HCN antibodies (HCV Ab), 4 UI. AZT, azathioprine; GC, glucocorticoids; IVIG, intravenous immunoglobulin.
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A 51-year-old man  with ACKD of unknown aetiology and
hypertension, who  began dialysis in 2005. His ﬁrst renal
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Occult HCV viral loadFig. 2 – Changes in conventional anti-HCV antibodies and occult
anti-HCN antibodies (HCV Ab), 4 UI. PBMC, peripheral blood mon
glucocorticoids; MMF,  mycophenolate mofetil; TG, thymoglobulintransplant failed immediately due to non-immunological arte-
rial thrombosis in October 2007. During that admission he
received 2 units of red blood cells. Transaminases were spo-
radically raised in 2009, with a sustained increase in December
2010 (maximum level 28/40 UI/L AST/ALT). Occult HCV was
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iagnosed with 14 700 copies/g total RNA in PBMC (RNA neg-
tive in serum on ultracentrifugation and high-sensitivity
nti-HCV core antibody negative). Ultrasound and FibroScan®
ere normal. Potential external contamination was tested for,
ut did not occur: viral PCR and serology were performed in
he other patients in the unit and the healthcare staff. No
ew cases of classic HCV infection were detected. The patient
eceived a second renal transplant in October 2013 and was
reated with thymoglobulin (TG), tacrolimus (FK), mycopheno-
ate (MMF), and corticoids. Seventeen months post-transplant,
BMC viral load was undetectable, and RNA on serum ultra-
entrifugation and high-sensitivity anti-HCV core antibody
oth remained negative (Fig. 2).
iscussion
he infectivity8 and pathogenicity of occult HCV have been
escribed, but there is still insufﬁcient experience to justify
CV eradication. Currently, only cases in research protocols
ave been treated.3
There is evidence, though very little, of HCV replica-
or activity in the presence of immunosuppressive stimuli.4
herefore, in hyperimmunised patients requiring aggressive
mmunosuppression in the peritransplant period, including
ong-term corticoid therapy, doubt remains as to whether pre-
ransplant antiviral therapy should be considered.
This letter presents the second and third cases from the
iterature of patients with occult HCV who received immuno-
uppressive therapy. These are the ﬁrst described cases with
CKD. In the ﬁrst case presented here, which occurred fol-
owing AZT, the intralymphocyte viral load did not increase,
nd even decreased to undetectable levels, whilst the antibody
itre increased. This suggests that the patient’s immune sys-
em, though supposedly weakened, overcame the viraemia.
n the second case, the viral load was cleared to negative,
ut without the production of immune antibodies against the
irus (there was an increase in the level of antibodies, but this
as transient and did not reach the laboratory threshold).
The observed activity of the immunity/virology relation-
hip cannot be explained based on this experience alone.
uiroga et al.9 demonstrated that occult HCV did induce a
D4+/CD8+ cellular response in immunocompetent patients,
ut without detection of speciﬁc antibodies. However, little is
nown about HCV activity in immunocompromised patients,
articularly when taking into account, the different types and
egrees of immunosuppression that exist, including that pro-
ortionally related to uraemia.onclusion
n conclusion, there is insufﬁcient evidence to justify antiviral
reatment in patients with chronic kidney disease and occult
CV, even when immunosuppressive treatment is antici-
ated. Therefore, we  remain expectant and await further
esults.(5):509–516 513
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